Dr. Martin Edwards is a senior advisor at Norwest, providing counsel to Norwest’s healthcare portfolio companies in the biotech space.

As a non-executive board member and consultant, Martin currently serves on two US public company boards (Verona and Inozyme) and one US private company (SiteOne). Until September 2023 he was a board member at Reata which was sold to Biogen and until August 2024 he was a board member at Morphic which was sold to Eli Lilly. He is also an advisor to investment houses, advising on their biotech investments, including performing deep diligence on opportunities.

Previously, Martin worked most of his career for the Novo group, apart from a 5-year period where he ran his own startup biotech company, listing it on the London stock market.

From 2003- 2021 Martin was Senior Partner at Novo Ventures, the venture capital arm of Novo Holdings.

Prior to Novo Ventures, Martin spent most of his Novo career in drug development, heading medical and regulatory departments in the UK, US and Japan. He was the worldwide head of drug development from 1994-1998.

He originally trained in medicine in Manchester, UK and worked in health service.

Martin holds an MBA from the University of Warwick.